Evidence mapPaperPMID 42293301Full record

ArticleCase reports in neurological medicine2026

Anti-Ma2 Antibody-Associated Paraneoplastic Cerebellar Degeneration Mimicking the Cerebellar Ataxic Subtype of Hashimoto's Encephalopathy: A Case Report.

Masato Okitsu, Shintaro Nojiri, Tomoya Kawazoe, Akihito Hao, Kazushi Takahashi

Abstract read
In one paragraph

Article in Case reports in neurological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Masato OkitsuDepartment of Neurology, Tokyo Toritsu Shinkei Byoin, Fuchu, Tokyo, Japan, tokyo.ac.jp.ORCID https://orcid.org/0000-0002-5145-3785
Shintaro NojiriDepartment of Neurology, Tokyo Toritsu Shinkei Byoin, Fuchu, Tokyo, Japan, tokyo.ac.jp.
Tomoya KawazoeDepartment of Neurology, Tokyo Toritsu Shinkei Byoin, Fuchu, Tokyo, Japan, tokyo.ac.jp.
Akihito HaoDepartment of Neurology, Tokyo Toritsu Shinkei Byoin, Fuchu, Tokyo, Japan, tokyo.ac.jp.
Kazushi TakahashiDepartment of Neurology, Tokyo Toritsu Shinkei Byoin, Fuchu, Tokyo, Japan, tokyo.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune cerebellar ataxia (ACA) is an immune-mediated cerebellar disorder arising from various underlying conditions. Because ACA is potentially treatable, identifying associated neuronal antibodies is important for diagnosis. We report the case of a 55-year-old woman with subacute progressive ataxia who presented with dysarthria and impaired handwriting and gait. Her scale for the assessment and rating of ataxia (SARA) score was 20.5, with particularly high subscores for gait and stance. She had a history of Hashimoto's thyroiditis. Laboratory testing showed markedly elevated antithyroid antibody levels with normal thyroid function, initially suggesting the cerebellar ataxic subtype of Hashimoto's encephalopathy (HE). Cerebral blood flow single-photon emission computed tomography revealed cerebellar hypoperfusion, which was most prominent in the superior cerebellar vermis. Intravenous methylprednisolone (1000 mg/day for 3 days) was administered; however, her response was poor. Further evaluation revealed positivity for anti-Ma2 antibodies, leading to a diagnosis of anti-Ma2-associated ACA. Subsequent intravenous immunoglobulin therapy improved the clinical symptoms and imaging findings, and the follow-up SARA score decreased to 10. Comprehensive imaging revealed no underlying malignancy. This case is unique not only because both rare diseases were key considerations in the differential diagnosis, but also because it is instructive in two respects: the construct of HE remains insufficiently specific and should not preclude consideration of alternative immune-mediated etiologies, and patients positive for anti-Ma2 antibody require sustained oncological surveillance, even in the absence of malignancy at presentation.

Indexed as

anti-Ma2 antibodyautoimmune cerebellar ataxiaHashimoto’s encephalopathyparaneoplastic neurological syndrome

Identifiers

PMID42293301
PMCPMC13263532

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.